aibioVCEL Vericel Corporation
Vericel (VCEL) news
Top story · Jul 30, 2026 · SEC filing 8-K
Vericel reports results
Latest Vericel news
We have not published a story on Vericel yet. When there is news, it will appear here.
What Vericel does
Vericel Corporation is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets two FDA-approved autologous cell therapy products, MACI and Epicel, and one FDA-approved specialty biologic product, NexoBrid. MACI is an autologous cellularized scaffold indicated for the repair of symptomatic, full-thickness cartilage defects of the knee in adults. In August 2024 the FDA approved a supplemental BLA expanding the MACI indication to add arthroscopic delivery, using custom MACI Arthro instruments that the company sells separately. Epicel is a permanent skin replacement Humanitarian Use Device indicated for deep-dermal or full-thickness burns comprising 30 percent or more of total body surface area. NexoBrid is a topically administered biological orphan product containing proteolytic enzymes, indicated for eschar removal in deep partial-thickness or full-thickness thermal burns, and it is licensed from MediWound Ltd. for North American rights. MediWound conducts NexoBrid manufacturing, primarily in Israel. The MACI membrane is supplied to Vericel exclusively by Matricel GmbH under a supply agreement.
| Product or program | What it is | Stage |
|---|---|---|
| MACI | Autologous cultured chondrocytes on a collagen scaffold for knee cartilage defects | FDA approved |
| MACI Arthro | Arthroscopic delivery of MACI with custom instruments | approved August 2024 |
| Epicel | Permanent skin replacement for severe burns | Humanitarian Use Device |
| NexoBrid | Topical proteolytic enzyme product for eschar removal in burns | FDA-approved specialty biologic |
Vericel annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $276.3 million | $237.2 million |
| Research and development | $27.6 million | $24.8 million |
| Net income (loss) | $16.5 million | $10.4 million |
| Cash from operations | $51.9 million | $58.2 million |
| Cash and equivalents | $100.1 million | $74.5 million |
| Short-term investments | $37.4 million | $41.7 million |
Questions about Vericel
What is the ticker symbol of Vericel?
Vericel Corporation trades under the ticker VCEL on NASDAQ.
Where is Vericel listed?
Vericel Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:ATQP; LSX:A12FU4.
What is the SEC CIK of Vericel?
The SEC Central Index Key (CIK) for Vericel Corporation is 887359. Its filings are on SEC EDGAR.
How many shares does Vericel have outstanding?
51,206,614 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-30.
Which country or territory is Vericel listed under?
Our directory records Vericel Corporation under United States.
What does Vericel do?
Our directory classifies Vericel Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Vericel?
The ISIN recorded for Vericel Corporation is US92346J1088.
Does aibio.space cover Vericel?
aibio.space lists Vericel Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Vericel incorporated?
SEC records list its state or country of incorporation as MI.
What does Vericel develop?
Vericel Corporation is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets two FDA-approved autologous cell therapy products, MACI and Epicel, and one FDA-approved specialty biologic product, NexoBrid.
What is MACI from Vericel?
MACI: Autologous cultured chondrocytes on a collagen scaffold for knee cartilage defects Stage: FDA approved.
What is MACI Arthro from Vericel?
MACI Arthro: Arthroscopic delivery of MACI with custom instruments Stage: approved August 2024.
What was Vericel's revenue last year?
$276.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Vericel profitable?
Vericel Corporation reported net income of $16.5 million for the fiscal year ended Dec 31, 2025, and generated $51.9 million of cash from operations, per its annual report to the SEC.
How much does Vericel spend on research and development?
$27.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Investor discussion: Vericel
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Vericel Corp
- CIK
- 887359
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- VCEL (Nasdaq)
- State or country of incorporation
- MI
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Phone
- 6175885555
- Shares outstanding
- 51,206,614 as of 2026-07-24 (10-Q filed 2026-07-30)
- Former names
- AASTROM BIOSCIENCES INC
Recent filings
Listing details
- Company
- Vericel Corporation
- Ticker
- VCEL
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US92346J1088
- Other listed symbols
- GETTEX:ATQP; LSX:A12FU4
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction